|
US10745382B2
(en)
|
2015-10-15 |
2020-08-18 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
EP3474845B1
(en)
|
2016-06-27 |
2024-03-20 |
ChemoCentryx, Inc. |
Immunomodulator compounds
|
|
US10144706B2
(en)
|
2016-09-01 |
2018-12-04 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
KR20230010826A
(ko)
|
2016-10-14 |
2023-01-19 |
프리시젼 바이오사이언시스 인코포레이티드 |
B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
|
|
KR102599339B1
(ko)
*
|
2016-12-20 |
2023-11-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제로서 유용한 화합물
|
|
WO2018124766A2
(ko)
|
2016-12-28 |
2018-07-05 |
주식회사 녹십자랩셀 |
키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
|
|
JP7150745B2
(ja)
|
2017-03-27 |
2022-10-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
免疫調節剤としての置換イソキノリン誘導体
|
|
BR102018007822A2
(pt)
|
2017-04-20 |
2018-11-06 |
Gilead Sciences, Inc. |
composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
|
|
US11130740B2
(en)
|
2017-04-25 |
2021-09-28 |
Arbutus Biopharma Corporation |
Substituted 2,3-dihydro-1H-indene analogs and methods using same
|
|
US10919852B2
(en)
|
2017-07-28 |
2021-02-16 |
Chemocentryx, Inc. |
Immunomodulator compounds
|
|
KR102670486B1
(ko)
|
2017-08-08 |
2024-05-28 |
케모센트릭스, 인크. |
마크로사이클릭 면역조절제
|
|
KR102774451B1
(ko)
|
2017-11-14 |
2025-02-28 |
앱클론(주) |
항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
|
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
JP7037667B2
(ja)
|
2017-12-20 |
2022-03-16 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
|
|
US11203610B2
(en)
|
2017-12-20 |
2021-12-21 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
US11414418B2
(en)
|
2018-01-23 |
2022-08-16 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
WO2019160882A1
(en)
|
2018-02-13 |
2019-08-22 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
WO2019165043A2
(en)
|
2018-02-22 |
2019-08-29 |
Chemocentryx, Inc. |
Indane-amines as pd-l1 antagonists
|
|
JP7050165B2
(ja)
|
2018-02-26 |
2022-04-07 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
|
|
US11578054B2
(en)
|
2018-03-01 |
2023-02-14 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
KR102591947B1
(ko)
|
2018-04-19 |
2023-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
TW202017569A
(zh)
|
2018-05-31 |
2020-05-16 |
美商佩樂敦治療公司 |
用於抑制cd73之組合物及方法
|
|
PE20210642A1
(es)
|
2018-07-13 |
2021-03-23 |
Gilead Sciences Inc |
Inhibidores de pd-1/pd-l1
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
CN109305934A
(zh)
*
|
2018-08-07 |
2019-02-05 |
成都海博锐药业有限公司 |
苯醚类衍生物及可药用盐、医药上的用途
|
|
CN110872275A
(zh)
*
|
2018-08-31 |
2020-03-10 |
深圳微芯生物科技股份有限公司 |
作为免疫调节剂的联苯化合物及其用途
|
|
US11236085B2
(en)
|
2018-10-24 |
2022-02-01 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
EP3873608A1
(en)
|
2018-10-31 |
2021-09-08 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
EP4371987B9
(en)
|
2018-10-31 |
2025-11-26 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
|
|
AU2019373702A1
(en)
|
2018-11-02 |
2021-06-24 |
Shanghai Maxinovel Pharmaceuticals Co., Ltd. |
Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
|
|
WO2020169058A1
(zh)
*
|
2019-02-21 |
2020-08-27 |
杭州阿诺生物医药科技有限公司 |
Pd-l1拮抗剂化合物
|
|
CN113574063B
(zh)
|
2019-03-07 |
2025-03-18 |
捷克共和国有机化学与生物化学研究所 |
3’3’-环二核苷酸及其前药
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
WO2020178769A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
AU2020246317A1
(en)
|
2019-03-22 |
2021-11-18 |
Guangzhou Maxinovel Pharmaceuticals Co., Ltd |
Small-molecule inhibitor of PD-1/PD-L1, pharmaceutical composition thereof with PD-L1 antibody, and application of same
|
|
WO2020198676A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
KR20210146348A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
BR112021022659A2
(pt)
|
2019-05-15 |
2022-03-29 |
Chemocentryx Inc |
Compostos triarílicos para o tratamento de doenças pd-l1
|
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
|
WO2020243570A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
JP2022534982A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよびその使用
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
PL3980413T3
(pl)
|
2019-06-07 |
2023-12-27 |
Janssen Sciences Ireland Unlimited Company |
Heterocykliczne immunomodulatory jako inhibitor punktu kontrolnego pdl1
|
|
CA3140588A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor
|
|
KR102841588B1
(ko)
|
2019-06-20 |
2025-08-01 |
케모센트릭스, 인크. |
Pd-l1 질환의 치료를 위한 화합물
|
|
KR102890201B1
(ko)
|
2019-07-10 |
2025-11-24 |
케모센트릭스, 인크. |
Pd-l1 억제제로서의 인단
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
US20220296619A1
(en)
|
2019-08-19 |
2022-09-22 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
CN112457308B
(zh)
*
|
2019-09-09 |
2024-01-02 |
上海长森药业有限公司 |
新型三环芳香杂环化合物，及其制备方法、药物组合物和应用
|
|
WO2021055994A1
(en)
|
2019-09-22 |
2021-03-25 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
CN112574183B
(zh)
*
|
2019-09-29 |
2022-07-08 |
南京华威医药科技集团有限公司 |
一种pd-1抑制剂及其制备方法和用途
|
|
HRP20241379T1
(hr)
|
2019-09-30 |
2024-12-20 |
Gilead Sciences, Inc. |
Cjepiva za hbv i postupci za liječenje hbv
|
|
ES3068390T3
(en)
|
2019-10-16 |
2026-05-29 |
Chemocentryx Inc |
Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
|
|
AU2020368392B2
(en)
|
2019-10-16 |
2026-01-08 |
Chemocentryx, Inc. |
Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
|
|
EP4054723A1
(en)
|
2019-11-08 |
2022-09-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for melanoma
|
|
US12410418B2
(en)
|
2019-12-06 |
2025-09-09 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
MX2022008016A
(es)
*
|
2019-12-26 |
2022-07-27 |
Adlai Nortye Biopharma Co Ltd |
Compuesto antagonista de pd-l1.
|
|
KR102987126B1
(ko)
|
2020-03-20 |
2026-07-07 |
길리애드 사이언시즈, 인코포레이티드 |
4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
|
|
CN111333629B
(zh)
*
|
2020-04-10 |
2021-03-05 |
颜建发 |
苯基-1h-吡唑类衍生物及其在抗肿瘤药物中的应用
|
|
KR20230041654A
(ko)
|
2020-05-05 |
2023-03-24 |
테온 테라퓨틱스, 인크. |
칸나비노이드 수용체 유형 2 (cb2) 조정제 및 그의 용도
|
|
MX2023002332A
(es)
|
2020-08-28 |
2023-03-21 |
Bristol Myers Squibb Co |
Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular.
|
|
IL300916A
(en)
|
2020-08-31 |
2023-04-01 |
Bristol Myers Squibb Co |
Cell localization signature and immunotherapy
|
|
WO2022052926A1
(zh)
|
2020-09-09 |
2022-03-17 |
广州再极医药科技有限公司 |
芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用
|
|
CA3196496A1
(en)
|
2020-10-23 |
2022-04-28 |
Laurence David TOMS |
Lag-3 antagonist therapy for lung cancer
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
EP4262829A4
(en)
|
2020-12-17 |
2025-01-01 |
Artiva Biotherapeutics, Inc. |
Expanded and stimulated natural killer cells
|
|
EP4262830A4
(en)
|
2020-12-17 |
2025-01-15 |
Artiva Biotherapeutics, Inc. |
TREATING CANCER WITH NK CELLS AND AN ANTIBODY DIRECTED TO CD20
|
|
CN117858719A
(zh)
|
2021-03-29 |
2024-04-09 |
朱诺治疗学股份有限公司 |
使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
|
|
KR20240024048A
(ko)
|
2021-04-08 |
2024-02-23 |
아티바 바이오테라퓨틱스, 인크. |
Nk 세포와 her2 표적 항체를 이용한 암 치료 방법
|
|
US20240366664A1
(en)
|
2021-04-08 |
2024-11-07 |
Artiva Biotherapeutics, Inc. |
Treatment of cancer with nk cells and an egfr targeted antibody
|
|
AU2022254978A1
(en)
|
2021-04-08 |
2023-11-16 |
Artiva Biotherapeutics, Inc. |
Treatment of cancer with nk cells and a cd20 targeted antibody
|
|
KR20240024047A
(ko)
|
2021-04-08 |
2024-02-23 |
아티바 바이오테라퓨틱스, 인크. |
Nk 세포와 cd38 표적 항체를 이용한 암 치료 방법
|
|
US20240269142A1
(en)
|
2021-05-13 |
2024-08-15 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
TWI861509B
(zh)
|
2021-06-11 |
2024-11-11 |
美商基利科學股份有限公司 |
Mcl-1抑制劑與抗體藥物接合物之組合
|
|
JP7900421B2
(ja)
|
2021-06-11 |
2026-08-04 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ
|
|
CN117355531A
(zh)
|
2021-06-23 |
2024-01-05 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
WO2023034530A1
(en)
|
2021-09-02 |
2023-03-09 |
Teon Therapeutics, Inc. |
Methods of improving growth and function of immune cells
|
|
WO2023077090A1
(en)
|
2021-10-29 |
2023-05-04 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
|
WO2023081730A1
(en)
|
2021-11-03 |
2023-05-11 |
Teon Therapeutics, Inc. |
4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
|
|
WO2023097211A1
(en)
|
2021-11-24 |
2023-06-01 |
The University Of Southern California |
Methods for enhancing immune checkpoint inhibitor therapy
|
|
AU2023213937A1
(en)
|
2022-01-26 |
2024-07-18 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
|
JP7851417B2
(ja)
|
2022-04-08 |
2026-04-24 |
ブリストル－マイヤーズ スクイブ カンパニー |
三次リンパ組織様構造の機械学習識別、分類、及び定量化
|
|
EP4554943A1
(en)
|
2022-07-14 |
2025-05-21 |
Teon Therapeutics, Inc. |
Adenosine receptor antagonists and uses thereof
|
|
WO2024088036A1
(zh)
*
|
2022-10-26 |
2024-05-02 |
西安新通药物研究股份有限公司 |
一种非对称性联苯衍生物及其制备方法与医药用途
|
|
TW202430637A
(zh)
|
2022-11-16 |
2024-08-01 |
美商戴瑟納製藥股份有限公司 |
Stat3靶向性寡核苷酸及其用途
|
|
KR20250123912A
(ko)
|
2022-12-21 |
2025-08-18 |
브리스톨-마이어스 스큅 컴퍼니 |
폐암에 대한 병용 요법
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
CN116332821B
(zh)
*
|
2023-04-06 |
2025-02-07 |
杭州国瑞生物科技有限公司 |
一种5-(2-氟苯基)-1h-吡咯-3-甲腈的制备方法
|
|
TW202608468A
(zh)
|
2024-05-13 |
2026-03-01 |
美商基利科學股份有限公司 |
組合療法
|
|
US20250345390A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|
|
WO2026035860A1
(en)
|
2024-08-07 |
2026-02-12 |
Teon Therapeutics, Inc. |
Formulations of adenosine receptor antagonist
|